# In a real-life setting, direct-acting antivirals to people who inject drugs with chronic hepatitis C in Turkey

Figen Sarigul<sup>1</sup>, Ülkü Üser<sup>1</sup>, Didem Sarı<sup>2</sup>, Behice Kurtaran<sup>1</sup>, Yusuf Önlen<sup>1</sup>, Ebubekir Senates<sup>3</sup>, Alper Gündüz<sup>1</sup>, Esra Zerdali<sup>1</sup>, Hasan Karsen<sup>4</sup>, AYŞE BATIREL<sup>1</sup>, Ritvan Karali<sup>5</sup>, Rahmet Güner<sup>6</sup>, Tansu Yamazhan<sup>1</sup>, Sukran Kose<sup>7</sup>, Nurettin Erben<sup>1</sup>, Nevin İnce<sup>8</sup>, Iftihar Koksal<sup>9</sup>, Nefise Oztoprak<sup>10</sup>, GÜLŞEN YÖRÜK<sup>1</sup>, Süheyla Kömür<sup>1</sup>, Tayibe Bal<sup>11</sup>, Sibel Yıldız Kaya<sup>12</sup>, ilkay bozkurt<sup>1</sup>, ÖZGÜR GÜNAL<sup>1</sup>, İlknur Esen Yıldız<sup>13</sup>, Dilara Inan<sup>14</sup>, Şener Barut<sup>1</sup>, Mustafa Namiduru<sup>1</sup>, Selma Tosun<sup>15</sup>, Kamuran Türker<sup>1</sup>, Alper Şener<sup>1</sup>, Kenan Hizel<sup>1</sup>, Nurcan Baykam<sup>16</sup>, Fazilet Duygu<sup>1</sup>, Hurrem Bodur<sup>17</sup>, Güray Can<sup>1</sup>, Hanefi Cem Gül<sup>1</sup>, AyÅe SAÄMAK TARTAR<sup>18</sup>, Guven Celebi<sup>10</sup>, Mahmut Sünnetci<sup>1</sup>, Oguz Karabay<sup>19</sup>, Hayat Kumbasar<sup>1</sup>, Fatma Sırmatel<sup>1</sup>, and Fehmi Tabak<sup>20</sup>

<sup>1</sup>Affiliation not available

<sup>2</sup>Istanbul Training and Research Hospital, Infectious Diseases <sup>3</sup>Medeniyet Universitesi Goztepe Egitim ve Arastirma Hastanesi <sup>4</sup>Harran University School of Medicine <sup>5</sup>Istanbul Universitesi-Cerrahpasa <sup>6</sup>Ankara Yildirim Beyazit University Faculty of Medicine <sup>7</sup>Ministry of Health Tepecik Hospital, Infectious Diseases Clinic <sup>8</sup>Duzce Universitesi <sup>9</sup>Karadeniz Technical University <sup>10</sup>Zonguldak Karaelmas University <sup>11</sup>Mustafa Kemal Universitesi Tavfur Ata Sokmen Tip Fakultesi <sup>12</sup>Sungurlu State Hospital <sup>13</sup>Recep Tavvip Erdogan University Training and Research Hospital <sup>14</sup>Akdeniz University Faculty of Medicine <sup>15</sup>University of Health Sciences Izmir Bozyaka Education and Research Hospital <sup>16</sup>Hitit University <sup>17</sup>Saglik Bilimleri Universitesi <sup>18</sup>Firat University, Faculty of Medicine <sup>19</sup>Sakarva University <sup>20</sup>Istanbul University-Cerrahpasa Cerrahpasa Faculty of Medicine

July 15, 2021

## Abstract

Introduction: People who inject drugs (PWID) should be treated in order to eliminate hepatitis C virus (HCV) in the world. Aims: The aim of this study was to compare direct acting antivirals (DAAs) treatment of HCV for PWID and non-PWID in real life setting. Materials and methods: We performed a prospective, non-randomized, observational multi-center cohort study in 37 centers. All patients treated with DAAs therapy between April 1, 2017 to February 28, 2019 were included. In total, 2,713 patients were included in the study among which 250 were PWID and 2,463 were non-PWID. Besides patient characteristics, treatment response, follow-up and side effects of treatment were also analyzed. Results: Genotype 1a and 3 were more prevalent in PWID infected patients (20.4% vs 9.9% and 46.8% vs 5.3%). The number of naïve patients was higher in PWID (90.7% vs 60.0%), while the number of patients with cirrhosis was higher in non-PWID (14.1% vs 3.7%). The loss of follow up was higher in PWID (29.6% vs 13.6%). There was no difference in the sustained virologic response at 12 weeks after treatment (98.3% vs 98.4%), but the end of treatment response was lower in PWID (96.2% vs 99.0%). In addition, the rate of treatment completion was lower in PWID (74% vs 94.4%). Conclusion: DAAs were safe and effective in PWID. Primary measures should be taken to prevent the loss of follow-up and poor adherence in PWID patients in order to achieve World Health Organization's objective of eliminating viral hepatitis.

#### Hosted file

IJCP HCV IVDU without fig and tbl MAIN TEXT .docx available at https://authorea.com/users/ 425722/articles/530492-in-a-real-life-setting-direct-acting-antivirals-to-people-whoinject-drugs-with-chronic-hepatitis-c-in-turkey

### Hosted file


Table 1. JVH docx.docx available at https://authorea.com/users/425722/articles/530492-ina-real-life-setting-direct-acting-antivirals-to-people-who-inject-drugs-with-chronichepatitis-c-in-turkey

#### Hosted file

JVH Table 2.docx available at https://authorea.com/users/425722/articles/530492-in-a-reallife-setting-direct-acting-antivirals-to-people-who-inject-drugs-with-chronic-hepatitisc-in-turkey

#### Hosted file

JVH Table 3.docx available at https://authorea.com/users/425722/articles/530492-in-a-reallife-setting-direct-acting-antivirals-to-people-who-inject-drugs-with-chronic-hepatitisc-in-turkey






Figure: 2. Outcome of antiviral therapy between PWID and non-PWID. SVR= sustained virologic response 12 weeks after treatment completion.